Drug Profile
Vididencel - Mendus AB
Alternative Names: Acute myeloid leukaemia vaccine - DCPrime; DCP-001; Leukemic dendritic cell vaccine - DCPrimeLatest Information Update: 04 Apr 2024
Price :
$50
*
At a glance
- Originator DCPrime; Immunicum
- Developer DCPrime; Mendus
- Class Antineoplastics; Cancer vaccines; Dendritic cell vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia
- Phase I/II Ovarian cancer
- Phase I Gastrointestinal stromal tumours
- Discontinued Multiple myeloma
Most Recent Events
- 04 Apr 2024 Discontinued - Preclinical for Multiple myeloma in USA (Parenteral) before April 2024 (Mendus pipeline, April 2024)
- 12 Mar 2024 Mendus enters a clinical trial collaboration agreement with Australian Leukemia and Lymphoma Group for phase II AMLM22-CADENCE trial in Acute myeloid leukemia
- 12 Mar 2024 Mendus and Australasian Leukaemia & Lymphoma Group plans a phase II AMLM22-CADENCE trial for Acute myeloid leukemia (Combination therapy) in April 2024